(2Z,4E)-ethyl 5-(2-((S)-2-(4-(benzyloxy)phenyl)-1-(cyclohexanecarboxamido)ethyl)-5-phenylthiazol-4-yl)-2,4-dimethylpenta-2,4-dienoate | 1056751-10-0

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: (2Z,4E)-ethyl 5-(2-((S)-2-(4-(benzyloxy)phenyl)-1-(cyclohexanecarboxamido)ethyl)-5-phenylthiazol-4-yl)-2,4-dimethylpenta-2,4-dienoate
• 英文别名: ethyl (2Z,4E)-5-[2-[(1S)-1-(cyclohexanecarbonylamino)-2-(4-phenylmethoxyphenyl)ethyl]-5-phenyl-1,3-thiazol-4-yl]-2,4-dimethylpenta-2,4-dienoate
• CAS: 1056751-10-0
• 化学式: C₄₀H₄₄N₂O₄S
• 分子量: 648.866
• InChiKey: HQYUVCZUOFIWQS-VINDIVFBSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  9.6
• 重原子数：
  47
• 可旋转键数：
  14
• 环数：
  5.0
• sp3杂化的碳原子比例：
  0.33
• 拓扑面积：
  106
• 氢给体数：
  1
• 氢受体数：
  6

反应信息

• 作为反应物：
  描述：

  (2Z,4E)-ethyl 5-(2-((S)-2-(4-(benzyloxy)phenyl)-1-(cyclohexanecarboxamido)ethyl)-5-phenylthiazol-4-yl)-2,4-dimethylpenta-2,4-dienoate 在 lithium hydroxide monohydrate 作用下， 以 1,4-二氧六环 、 水 为溶剂， 以90%的产率得到(2Z,4E)-5-(2-((S)-2-(4-(benzyloxy)phenyl)-1-(cyclohexanecarboxamido)ethyl)-5-phenylthiazol-4-yl)-2,4-dimethylpenta-2,4-dienoic acid
  参考文献：
  名称：

  Design, synthesis, and biological evaluation of novel 2-ethyl-5-phenylthiazole-4-carboxamide derivatives as protein tyrosine phosphatase 1B inhibitors with improved cellular efficacy

  摘要：

  Protein tyrosine phosphatase 1B (PTP1B) is implicated as a key negative regulator of the insulin and leptin signal-transduction pathways. PTP1B inhibitors have emerged as attractive and potent pharmaceutical agents for the treatment of type 2 diabetes and obesity. We identified a series of 2-ethy1-5-phenylthiazole-4-carboxamide (PTA) derivatives, inspired from the ACT scaffold of Scleritodermin A, as a novel class of PTP1B inhibitors. Structure-activity relationship (SAR) analysis and docking studies revealed the molecular basis of PTP1B inhibition by these compounds. PTA derivative 18g was capable of inhibiting intracellular PTP1B and subsequently activating the insulin signaling pathway. Treatment of cells with 18g markedly increased the phosphorylation levels of IRP and Akt as well as the rate of glucose uptake. (C) 2013 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2013.09.017
• 作为产物：
  描述：

  benzoylaminoacetic acid ethyl ester 在 劳森试剂 、 4-二甲氨基吡啶 、 lithium aluminium tetrahydride 、 18-冠醚-6 、 双(三甲基硅烷基)氨基钾 、 sodium hydride 、 盐酸-N-乙基-Nˊ-(3-二甲氨基丙基)碳二亚胺 、 三乙胺 、 N,N-二异丙基乙胺 、 三氟乙酸 、 2-碘酰基苯甲酸 作用下， 以 四氢呋喃 、 二氯甲烷 、 二甲基亚砜 、 甲苯 、 mineral oil 为溶剂， 反应 21.5h， 生成 (2Z,4E)-ethyl 5-(2-((S)-2-(4-(benzyloxy)phenyl)-1-(cyclohexanecarboxamido)ethyl)-5-phenylthiazol-4-yl)-2,4-dimethylpenta-2,4-dienoate
  参考文献：
  名称：

  Design, synthesis, and biological evaluation of novel 2-ethyl-5-phenylthiazole-4-carboxamide derivatives as protein tyrosine phosphatase 1B inhibitors with improved cellular efficacy

  摘要：

  Protein tyrosine phosphatase 1B (PTP1B) is implicated as a key negative regulator of the insulin and leptin signal-transduction pathways. PTP1B inhibitors have emerged as attractive and potent pharmaceutical agents for the treatment of type 2 diabetes and obesity. We identified a series of 2-ethy1-5-phenylthiazole-4-carboxamide (PTA) derivatives, inspired from the ACT scaffold of Scleritodermin A, as a novel class of PTP1B inhibitors. Structure-activity relationship (SAR) analysis and docking studies revealed the molecular basis of PTP1B inhibition by these compounds. PTA derivative 18g was capable of inhibiting intracellular PTP1B and subsequently activating the insulin signaling pathway. Treatment of cells with 18g markedly increased the phosphorylation levels of IRP and Akt as well as the rate of glucose uptake. (C) 2013 Elsevier Masson SAS. All rights reserved.

  DOI：

  10.1016/j.ejmech.2013.09.017

文献信息

• Protein Tyrosine Phosphatase 1B Inhibitor, Preparation Methods and Uses Thereof
  申请人：Nan Fajun

  公开号：US20100197927A1

  公开（公告）日：2010-08-05

  PTP1B inhibitors with the following structure (formula I). Experiments indicate that these inhibitors can effectively inhibit the activity of protein tyrosine phosphatase 1B (PTP1B). They can be used as insulin sensitisers. They can be used to prevent, delay or treat diseases which are related to insulin antagonism mediated by PTP1B, especially diabetes type II and obesity. The invention also provides methods for preparing these inhibitors.
• US8183383B2
  申请人：——

  公开号：US8183383B2

  公开（公告）日：2012-05-22
• Design, synthesis, and biological evaluation of novel 2-ethyl-5-phenylthiazole-4-carboxamide derivatives as protein tyrosine phosphatase 1B inhibitors with improved cellular efficacy
  作者：Yue-Ting Chen、Chun-Lan Tang、Wei-Ping Ma、Li-Xin Gao、Yi Wei、Wei Zhang、Jing-Ya Li、Jia Li、Fa-Jun Nan

  DOI：10.1016/j.ejmech.2013.09.017

  日期：2013.11

  Protein tyrosine phosphatase 1B (PTP1B) is implicated as a key negative regulator of the insulin and leptin signal-transduction pathways. PTP1B inhibitors have emerged as attractive and potent pharmaceutical agents for the treatment of type 2 diabetes and obesity. We identified a series of 2-ethy1-5-phenylthiazole-4-carboxamide (PTA) derivatives, inspired from the ACT scaffold of Scleritodermin A, as a novel class of PTP1B inhibitors. Structure-activity relationship (SAR) analysis and docking studies revealed the molecular basis of PTP1B inhibition by these compounds. PTA derivative 18g was capable of inhibiting intracellular PTP1B and subsequently activating the insulin signaling pathway. Treatment of cells with 18g markedly increased the phosphorylation levels of IRP and Akt as well as the rate of glucose uptake. (C) 2013 Elsevier Masson SAS. All rights reserved.